

FOR IMMEDIATE RELEASE

IMMUNOXYEL CLINICAL STUDY SUCCESS RECEIVES U.S. CRDF RECOGNITION, AWARD AND GRANT

- Immunoxel clinical study awarded
- Development grant from U.S. Civilian Research & Development Foundation
- Immunoxel featuring at the 4th South African AIDS Conference this week

Sydney NSW, 2 April 2009 -- Zodiac Capital Limited (NSX: ZOD) is pleased to advise that Immunoxel has received major recognition through an award received this week from the U.S. Civilian Research & Development Foundation (CRDF). This award marks an important milestone in the ongoing development and global commercialisation of Immunoxel as an adjunct immunotherapeutic agent specifically designed for the treatment of tuberculosis and AIDS.

The U.S. CRDF is a major non-profit granting agency authorized by the U.S. Congress and established in 1995 by the National Science Foundation. This unique public-private partnership promotes international scientific and technical collaboration through grants, technical resources, and training.


The CRDF panel of judges gathered on March 31, 2009 at the CRDF Innovation Forum in Kiev and selected the joint Lisichansk TB Dispensary (Clinical collaborator) and Ekomed (Immunoxel manufacturer and Licensor) proposal as a top priority project. They have awarded the Immunoxel clinical collaborators, Dr. Galyna Kutsyna and her clinical team of doctors from the Lisichansk TB Dispensary and Luhansk Medical University, a grant to conduct an Immunoxel double-blind, placebo-controlled clinical trial. The CRDF decision culminated several months of critical evaluation by peer reviewers in the USA and the Ukraine.

Stirling Products and Zodiac Capital congratulate Dr. Galyna Kutsyna and her team as well as the Immunoxel developer Volodymyr Pylypchuk who stated: "The CRDF award represents for us the international recognition of our work and especially the effort of our clinical collaborators without whom we would ever have dreamed to be honoured in such a way. We are very proud that we have been selected among many other worthy projects from the Ukraine and confident that the award that the US-based science agency bestowed on us will allow us to carry on further work in confirming the potential of Immunoxel in treating patients with TB as well as HIV infection".


As presented to the U.S. CRDF the use of Immunoxel as an adjunct immunomodulator to existing anti TB treatment (ATT):

- Tunes the Immune System against **any** form of TB
- Enhances efficacy of TB drugs 2-10 fold
- Shortens therapy duration 3-12 fold
- Reduces and reverses toxicity of current TB drugs
- Is market ready for TB and TB/HIV treatment

EFFICACY



TREATMENT TIME



In earlier published clinical trials Immunoxel has been shown to be very safe and highly effective as an immune adjuvant in TB patients including patients with multi-drug (MDR-TB) and extensively drug resistant TB (XDR-TB). Similar benefits were observed in patients with TB who were also dually infected with HIV (TB/HIV). While these results were published in at least nine peer-reviewed medical journals, no double-blind, placebo-controlled clinical trials have been conducted to date. The CRDF grant will allow Dr. Galyna Kutsna and her team to carry out such a trial, the results of which are expected to become public towards the end of this year.

The WHO estimates that globally, about one-third of the world's population is infected with the Mycobacterium tuberculosis bacteria that cause TB, and each year approximately 9 million people become ill with the disease, and 2 million of those die. TB patients with HIV are 30 times more likely to die and treatment options for them are limited. The WHO's annual report on TB issued on March 24, 2009 - the World TB Day - indicated that one in four tuberculosis deaths is HIV related, which is twice as many as had been recognized previously. In addition about half a million people had multidrug-resistant TB in 2007. But due to lack of adequate treatment, which can be costly and complicated, treatment options for TB patients, particularly those living in places such as Africa, India, China and the Ukraine are limited.

As announced yesterday, Immunoxel is being presented at the 4th South African AIDS Conference being held in Durban this week following the success achieved in another clinical trial where Immunoxel, as well as successfully treating co-infected TB/HIV patients, also demonstrated its potential to halve the mortality rate in terminally-ill TB/HIV patients.



Zodiac Capital Limited, ACN 126 263 170
Level 1, 275 George Street, Sydney NSW 2000
Australia
Phone +61 2 9299 9270
Fax +61 2 9299 9276

Immunoxel is one of the 26 phytopharmaceutical (botanical) products being commercialised globally under a Zodiac Capital License Agreement that, subject to shareholder approval, the Company has agreed to joint venture with Stirling Products Limited as has previously been advised to the market on 25 March 2009. An Independent Expert's Report on the joint venture agreement is currently being prepared for inclusion and consideration at a Stirling Products Shareholders Meeting proposed for approximately May 11, 2009 and for Zodiac Capital on a date to be advised.

CONTACT: For further detail or inquiry please contact

Dr Allen Bain allen.bain@zodiaccap.com

Peter Squire peter.squire@zodiaccap.com

Zodiac Capital Limited

Level 1, 275 George Street

Sydney NSW 2000

Tel: +61(0)2 9299 9270